Internal Medicine, Hematology & Oncology · Howard Beach, NY
NPI
1306828751
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
16150 92nd St
Howard Beach, NY, 11414
Phone (718) 848-0475
Groups this clinician bills Medicare through
Medicare paid, 2024
$558K
254,421 services
Medicare patients, 2024
377
Average age 75
Drug cost, 2024
$2.5M
1,555 prescriptions
Company payments, 2025
$756
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Delfino M Crescenzo was code J0174 (injection, lecanemab-irmb, 1 mg), 119,805 times for 12 patients. In total Delfino M Crescenzo billed 254,421 services in 74 codes, and Medicare paid $558K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-01-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0174 Injection, lecanemab-irmb, 1 mg | Office | 119,805 | 12 | $1.05 | $126K |
| J1756 Injection, iron sucrose, 1 mg | Office | 89,312 | 127 | $0.17 | $15K |
| J2916 Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | Office | 1,700 | 62 | $1.42 | $2,416 |
| 36415 Venipuncture Blood Collection | Office | 1,602 | 255 | $3.50 | $5,602 |
| 99213 Office E&M - Established | Office | 1,059 | 253 | $80.20 | $85K |
| 96365 Intravenous Infusion, Hydration | Office | 783 | 189 | $57.61 | $45K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 559 | 148 | $0.50 | $277 |
| 99214 Office E&M - Established | Office | 246 | 131 | $99.60 | $25K |
| 96413 Chemotherapy Administration | Office | 168 | 25 | $121.99 | $20K |
| 96361 Intravenous Infusion, Hydration | Office | 139 | 19 | $11.06 | $1,538 |
| J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 134 | 27 | $0.99 | $132 |
| 96372 Injection Administration | Office | 116 | 38 | $12.84 | $1,490 |
| 96375 Injection Administration | Office | 115 | 18 | $14.21 | $1,634 |
| 96366 Intravenous Infusion, Hydration | Office | 114 | 14 | $19.20 | $2,189 |
| 96367 Intravenous Infusion, Hydration | Office | 84 | 15 | $26.11 | $2,194 |
By year: 2022 $335K for 40,179 services; 2023 $267K for 78,900 services; 2024 $558K for 254,421 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,602 | 255 | $3.50 | $5,602 |
Medicare prescription drug claims, 2024
In 2024, the drug Delfino M Crescenzo prescribed most often to Medicare patients was Allopurinol, with 79 prescriptions and refills. In total Delfino M Crescenzo wrote 1,555 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Allopurinol Generic | 79 | 135 | 16 | $387 |
| Tamoxifen Citrate Generic | 68 | 112 | 14 | $951 |
| Meloxicam Generic | 59 | 59 | 14 | $122 |
| Promacta Eltrombopag Olamine | 57 | 61 | 12 | $453K |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 53 | 62 | 11 | $281 |
| Procrit Epoetin Alfa | 40 | 40 | 17 | $155K |
| Ondansetron Hcl Generic | 38 | 39 | Under 11 | $437 |
| Hydroxyurea Generic | 37 | 65 | 11 | $685 |
| Atorvastatin Calcium Generic | 37 | 43 | Under 11 | $260 |
| Amlodipine Besylate Generic | 36 | 52 | Under 11 | $34.67 |
| Dexamethasone Sodium Phosphate Generic | 29 | 30 | Under 11 | $174 |
| Omeprazole Generic | 27 | 43 | Under 11 | $228 |
| Gabapentin Generic | 25 | 25 | Under 11 | $293 |
| Xarelto Rivaroxaban | 24 | 28 | Under 11 | $15K |
| Metformin Hcl Generic | 21 | 35 | Under 11 | $49.05 |
Brand drugs: - claims; generic drugs: 1,143 claims; opioid claims: 75.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Delfino M Crescenzo $756 ($756 in general payments such as food, travel and fees) from 18 companies. The largest payer was Janssen Biotech, Inc. with $209.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 4 | $209 |
| Incyte Corporation INCY | 3 | $83.69 |
| Daiichi Sankyo Inc. 4568.T | 3 | $66.99 |
| GlaxoSmithKline, LLC. GSK | 3 | $61.56 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $50.73 |
| Invivyd Inc IVVD | 2 | $39.99 |
| Octapharma USA, Inc. | 2 | $36.86 |
| Agios Pharmaceuticals, Inc. AGIO | 2 | $34.94 |
| Merck Sharp & Dohme LLC MRK | 1 | $23.28 |
| Array Biopharma Inc PFE | 1 | $19.7 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.